Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
VNDA Vanda Pharmaceuticals
9.670
-0.030-0.31%
Post Mkt Price
9.6700.0000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Assets
Current assets
Cash, cash equivalents and short term investments
11.19% 440.86M 15.08% 435.18M 17.7% 432.81M 17.7% 432.81M
-Cash and cash equivalents
1.72% 58.23M -7.22% 66.93M -14.68% 52.07M -14.68% 52.07M
-Short-term investments
12.79% 382.63M 20.33% 368.25M 24.14% 380.74M 24.14% 380.74M
Receivables
-22.34% 28.81M -3.1% 30.5M 8.09% 32.47M 8.09% 32.47M
-Accounts receivable
-22.34% 28.81M -3.1% 30.5M 8.09% 32.47M 8.09% 32.47M
Inventory
41.8% 1.5M -5.22% 1.29M -19.92% 1.03M -19.92% 1.03M
Prepaid assets
114.22% 25.74M 147.43% 25.31M 18.9% 12M 18.9% 12M
Total current assets
11.25% 496.9M 16.87% 492.27M 16.9% 478.3M 16.9% 478.3M
Non current assets
Net PPE
-16.11% 11.35M -15.48% 11.86M -15.14% 12.39M -15.14% 12.39M
-Gross PPE
-16.11% 11.35M -15.48% 11.86M -3.81% 21.76M -45.25% 12.39M
-Accumulated depreciation
-- -- -- -- -16.8% -9.38M -- --
Goodwill and other intangible assets
-7.19% 19.32M -7.02% 19.7M -6.86% 20.08M -6.86% 20.08M
-Other intangible assets
-7.19% 19.32M -7.02% 19.7M -6.86% 20.08M -- --
Non current deferred assets
-7.57% 72.69M -11.89% 70.8M -8.14% 74.88M -8.14% 74.88M
Other non current assets
10.56% 8.85M 39.74% 8.93M 22.68% 8.15M 22.68% 8.15M
Total non current assets
-7.26% 112.21M -8.75% 111.29M -7.1% 115.49M -7.1% 115.49M
Total assets
7.3% 609.1M 11.11% 603.56M 11.31% 593.79M 11.31% 593.79M
Liabilities
Current liabilities
Payables
173.32% 21.96M 172.8% 19.43M -0.99% 6.8M -- --
-accounts payable
675.25% 16.41M -- 14.33M -- 925K -- --
-Other payable
-6.24% 5.55M -28.39% 5.1M -14.46% 5.87M -- --
Current accrued expenses
21.12% 21.32M 108.23% 26.54M 62.54% 18.81M -- --
Current provisions
-5.07% 38.16M 10.28% 39.35M 16.13% 39.98M 16.13% 39.98M
Current debt and capital lease obligation
4.81% 2.25M 8.04% 2.3M 9.16% 2.31M -- --
-Current capital lease obligation
4.81% 2.25M 8.04% 2.3M 9.16% 2.31M -- --
Current liabilities
22.8% 88.4M 46.87% 90.74M 12.87% 74.42M 12.87% 74.42M
Non current liabilities
Long term debt and capital lease obligation
-13.54% 9.29M -13.17% 9.66M -12.54% 10.06M -12.54% 10.06M
-Long term capital lease obligation
-13.54% 9.29M -13.17% 9.66M -12.54% 10.06M -12.54% 10.06M
Other non current liabilities
-22.43% 2.87M -61.09% 1.03M 59.23% 4.39M 59.23% 4.39M
Total non current liabilities
-15.81% 12.15M -22.4% 10.69M 1.34% 14.45M 1.34% 14.45M
Total liabilities
16.35% 100.55M 34.24% 101.44M 10.82% 88.86M 10.82% 88.86M
Shareholders'equity
Share capital
1.79% 57K 0% 56K 1.82% 56K 1.82% 56K
-common stock
1.79% 57K 0% 56K 1.82% 56K 1.82% 56K
-Preferred stock
-- 0 -- 0 -- 0 -- --
Retained earnings
6.14% -168.03M 9.58% -170.61M 16.8% -164.18M 16.8% -164.18M
Paid-in capital
2.71% 677.96M 2.74% 674M 2.91% 669.22M 2.91% 669.22M
Gains losses not affecting retained earnings
-1489.32% -1.43M -791.67% -1.33M -173.22% -175K -173.22% -175K
Total stockholders'equity
5.68% 508.55M 7.38% 502.12M 11.4% 504.93M 11.4% 504.93M
Total equity
5.68% 508.55M 7.38% 502.12M 11.4% 504.93M 11.4% 504.93M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
CEO: Dr. Mihael Hristos Polymeropoulos,M.D.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...